Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Efficacy and Safety of JAK inhibitors for AD
Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.
EP: 1.Expert Perspectives on the Rapid Expansion of Atopic Dermatitis Treatments
EP: 2.Atopic Dermatitis Treatment Biological Targets
EP: 3.Use of JAK Inhibitors in Clinical Practice
EP: 4.Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management
EP: 5.Final Thoughts for Atopic Dermatitis Treatment
EP: 6.Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 7.Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 8.Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 9.Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 10.Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 11.Expert Perspective on the Care of Patients with Atopic Dermatitis
EP: 12.Role of Disease Severity in Topical vs Systemic AD Treatment
Now Viewing
EP: 13.Efficacy and Safety of JAK inhibitors for AD
EP: 14.Optimizing Patient Outcomes with JAK Inhibitors
Related Videos
Related Content
